HPS-4/TIMI 65/ORION-4: Cardiovascular outcomes study with inclisiran

October 2026

Baseline data from the ORION-4 study with inclisiran in over 16,000 patients with established atherosclerotic cardiovascular disease. Results are expected early 2027.

Mafham M, Zayed M, Collins R, et al. HPS-4/TIMI 65/ORION-4: A double-blind randomized placebo-controlled trial assessing the effects of inclisiran on clinical outcomes among people with atherosclerotic cardiovascular disease: Trial design, recruitment, and baseline characteristics. Am Heart J 2026; https://doi.org/10.1016/j.ahj.2026.107546

STUDY SUMMARY

Objective

ORION-4 study is evaluating the cardiovascular efficacy and safety of inclisiran, a short interfering RNA (siRNA) among individuals with pre-existing atherosclerotic cardiovascular disease (ASCVD).

 

 

Study design

Double-blind, randomized, placebo-controlled, cardiovascular outcomes study conducted in the UK and USA. Patients were randomized in a 1:1 ratio to either inclisiran 300 mg or matching placebo (given by subcutaneous injection on the day of randomization, at 3 months and then every 6 months) for a planned median duration since randomization of at least 5 years.    

 

 

Study population

ORION-4 aimed to recruit at least 15,000 individuals with established ASCVD. Men aged at least 40 years (initially at least 55 years), and women aged at least 55 years at sufficient risk of the primary efficacy outcome were eligible. Initially, patients were screened for trial eligibility if total cholesterol was ≥155 mg/dL (4.0 mmol/L); this threshold was subsequently reduced to ≥135 mg/dL (≥3.5 mmol/l) in July 2021 and subsequently to ≥116 mg/dL (≥3.0 mmol/L) in June 2022 on the recommendation of the Steering Committee.  

 

 

Main study variables

The primary efficacy outcome was major adverse cardiovascular events (MACE), defined as the composite of coronary heart disease (CHD) death, myocardial infarction, fatal or non-fatal ischaemic stroke, or urgent coronary revascularization. Secondary efficacy outcomes included i) MACE in individuals on high-intensity statin at baseline; ii) the composite outcome of CHD death or myocardial infarction; and iii) cardiovascular death.

 

 

Methods

ORION-4 is led by the Clinical Trial Service Unit (CTSU) based at the University of Oxford, Oxford, in collaboration with the TIMI Study Group, Brigham and Women’s Hospital, Harvard Medical School, Boston.

 

Potential eligible individuals entered the single-blind pre-randomization run-in phase and received a subcutaneous injection of placebo.  This phase was intended to help identify, and exclude before randomization, those individuals who would be unlikely to comply with long-term study treatment and follow-up.  Eligible patients were randomized and received the first study treatment at a visit 8 weeks later and were requested to return for follow-up after 3 months, and thereafter every 6 months until the end of the study. Non-fasting blood samples were collected for central laboratory analysis at randomization and selected follow-up visits. Non-study lipid lowering therapy (including statin treatment) was the responsibility of the individual’s usual doctor throughout the study.

 

An independent Data Monitoring Committee was responsible for review of interim unblinded analyses of all serious adverse events and other study outcomes, including a single interim analysis for efficacy which occurred in 2025. The primary assessment is an intention-to-treat comparison of the effect of inclisiran on MACE over a median follow-up since randomization of at least 5 years and with at least 1700 individuals experiencing an adjudicated MACE.

 

Key results

Of 33,461 individuals screened for study eligibility, 18,569 entered the single-blind run-in phase on placebo, with 16,124 subsequently randomized to the study. Overall, 13,190 (82%) patients were enrolled at 109 sites in the UK, and 2934 (18%) at 84 sites in the US. Baseline characteristics of these patients are summarized in Table 1.    

 

Table 1. Baseline characteristics of the ORION-4 patient population

 

UK

(N=13190)

USA

(N=2934)

Total

(N=16124)

No. (%) male

9565 (73)

1694 (58)

11259 (70)

Mean (SD) age, years

70.4 (8.0)

68.2 (8.2)

70.0 (8.1)

  <65 years, %

26%

34%

28%

Statin, no. (%)

11474 (87)

2261 (77)

13735 (85)

  Intensive

6893 (52)

1596 (54)

8489 (53)

  Moderate/low

4581 (35)

665 (23)

5246 (33)

  None

1716 (13)

673 (23)

2389 (15)

ASCVD, no. (%)

 

 

 

  CHD

10134 (77)

2414 (82)

12548 (78)

  Ischemic stroke

2795 (21)

722 (25)

3517 (22)

  PAD

1948 (15)

513 (17)

2461 (15)

Diabetes, no. (%)

2650 (20)

1092 (37)

3742 (23)

Lipids, Mean (SD), mg/dL

 

 

 

Total cholesterol

184 (38)

199 (50)

186 (41)

LDL cholesterol

94 (30)

105 (38)

96 (32)

CHD coronary heart disease; PAD peripheral artery disease; SD standard deviation

 

The overall study population was predominantly male (70%), older (mean age 70 years, with about two-thirds aged at least 65 years), and had established coronary heart disease (78%). Most patients were receiving statin treatment, with about half (53%) on an intensive regimen. Few patients were receiving other lipid-modifying therapy (8% on ezetimbe, 2% on a fibrate and less than 1% on bempedoic acid or icosapent ethyl). Baseline mean LDL-C was 96 mg/dL (2.49 mmol/L) and was similar among participants on high- and moderate/low-intensity statin regimens (87 mg/dL [2.25 mmol/l] and 93 mg/dL [2.41 mmol/L], respectively).

Author conclusions

Inclisiran potentially offers a scalable lipid-lowering treatment, either alone or in combination with other agents. ORION-4 will evaluate the clinical efficacy of inclisiran and provide a robust assessment of the safety of prolonged use of an siRNA therapeutic.

Comment

Consistent with other cardiovascular outcomes studies with PCSK9-targeted therapy (1,2), baseline data for ORION-4 define an older patient population with established ASCVD, predominantly CHD. While most patients were receiving a statin, only about half were on an intensive regimen. Moreover, despite being at high cardiovascular risk, 15% did not receive statin therapy. The use of other lipid modifying therapy was minimal.

The results of ORION-4 are eagerly anticipated in early 2027, to evaluate whether inclisiran, against a background of moderate to intensive statin therapy, reduces the residual risk of cardiovascular events in patients with established ASCVD.

References

  1. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients

with cardiovascular disease. N Engl J Med 2017; 376: 1713–22.

  1. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018; 379: 2097–107.

Key words: ORION-4; inclisiran; siRNA therapeutic; PCSK9-targeted therapy; cardiovascular outcomes study